Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2003;Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida. Año 2003

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 3, 2004, Pages 160-176

  Berenguer, Juan ^a   Laguna, Fernando ^b   López Aldeguer, José ^c   Moreno, Santiago ^d,n   Arribas, José R ^b   Arrizabalaga, Julio ^e   Baraia, Josu ^f   Casado, José Luis ^d   Cosín, Jaime ^a   Polo, Rosa ^g   González García, Juan ^b   Iribarren, José A ^e   Kindelán, José M ^h   Lopez Bernaldo De Quiros, Juan C ^a   López Vélez, Rogelio ^d   Lorenzo, Juan F ⁱ   Lozano, Fernando ^j   Mallolas, Josep ^k   Miró, José M ^k,o   Pulido, Federico ^l   Ribera, Esteban ^m   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Hospital Nuestra Senora de Aranzazu   (Spain)

^f HOSPITAL DE BASURTO   (Spain)

^g Sec del Plan Nacional sobre el Sida   (Spain)

^h Hospital Universitario Reina Sofia Cordoba   (Argentina)

ⁱ HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^j HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ Hospital Vall d'Hebron ^*

^o INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

more..

Author keywords

HIV; Opportunistic infections; Prophylaxis; Withdrawal of prophylaxis

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPRENAVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; BCG VACCINE; CIDOFOVIR; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; ETHAMBUTOL; FAMCICLOVIR; FLUCONAZOLE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HEPATITIS B VACCINE; INDINAVIR; ISONIAZID; ITRACONAZOLE; LOPINAVIR; NELFINAVIR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL INFECTION; DATA ANALYSIS; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MEDICAL SOCIETY; MYCOSIS; OPPORTUNISTIC INFECTION; PARASITOSIS; PRACTICE GUIDELINE; REVIEW; VIRUS INFECTION;

EID: 11144353623     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058025     Document Type: Review

References (169)

1. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9.
2. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
3. Palella FJ Jr, Dalaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
4. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos Al, Katzenstein T, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study. Ann Intern Med 1999;130:570-7.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
6. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-6.
7. Berenguer J, Laguna F, López-Aldeguer J, Moreno S. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en la era del tratamiento antirretroviral de gran actividad. Recomendaciones de GESIDA/Plan Nacional Sobre el SIDA. Enferm Infecc Microbiol Clin 2000;18:457-68.
8. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4.
9. Jacobson MA. Cytomegalovirus retinitis: New developments in prophylaxis and therapy. AIDS Clin Rev 1997:249-69.
10. Casado JL, Arrizabalaga J, Montes M, Marti-Belda P, Tural C, Pinilla J, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group. Aids 1999;13:1497-502.
11. Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. Aids 1998;12:613-8.
12. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346:1119-26.
13. Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000;283:653-7.
14. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125:292-300.
15. Karavellas MP, Plummer DJ, Macdonald JC, Torriani FJ, Shufelt CL, Azen SP, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700.
16. Centers for Disease Control and Prevention. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. En: www.hivatis.org; 2001; p. 1-65.
17. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996;334:1491-7.
18. Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. Aids 1998;12:269-77.
19. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:105-14.
20. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995;333:615-20.
21. Curran M, Noble S. Valganciclovir. Drugs 2001;61:1145-50; discussion 1151-2.
22. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997;337:83-90.
23. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-70.
24. Perry CM, Balfour JA. Fomivirsen. Drugs 1999;57:375-80.
25. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998;158:957-69.
26. Tural C, Romeu J, Sirera G, Andreu D, Conejero M, Ruiz S, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-3.
27. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998;105:1259-64.
28. Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999;282:1633-7.
29. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
30. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. Aids 2001;15:23-31.
31. Berenguer J, González J, Pulido F, Padilla B, Casado JL, Rubio R, et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Infect Dis 2002;34:394-7.
32. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51(RR-6):1-78.
33. Centers for Disease Control and Prevention. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48(RR-6):1-5.
34. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1996;45(RR-11):1-36.
35. González-García J, Guerra L, Amela C, Del Amo J, Bruguera M, Castilla J, et al. Coinfección por VIH y virus de las hepatitis A, B y C en pacientes adultos. Revisión y recomendaciones de GESIDA/PNS. www.gesidascime.com. En: Grupo de trabajo para la elaboración de recomendaciones sobre las hepatitis virales en pacientes infectados por el VIH; 2002.
36. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
37. Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003;34:304-7.
38. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002;51(RR-3):1-31.
39. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, et al. Clinical course and prognostic factors of progressive multi focal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003;36:1047-52.
40. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
41. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-5.
42. Secretaría del Plan Nacional sobre el SIDA. Tuberculosis en pacientes infectados por el virus de la inmunodeficiencia humana. Madrid: Ministerio de Sanidad y Consumo, 2002.
43. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: Revised recommendations. Centers for Disease Control and Prevention. Morb Mortal Wkly Rep 1997;46(RR-15):1-10.
44. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-8.
45. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997;337:315-20.
46. Rivero A, López-Cortes L, Castillo R, Lozano F, Garcia MA, Díez F, et al. Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea. Enferm Infecc Microbiol Clin 2003;21:287-92.
47. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. Centers for Disease Control and Prevention. Morb Mortal Wldy Rep 1998;47(RR-20):1-58.
48. th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco; 1999.
49. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268:504-9.
50. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Pérez-Tascó n M, Miralles P, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993;119:194-8.
51. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. Aids 1993;7:1345-9.
52. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342(8866):268-72.
53. Moreno S, Miralles P, Díaz MD, Baraia J, Padilla B, Berenguer J, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Arch Intern Med 1997;157:1729-34.
54. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial. Aids 1997;11:875-82.
55. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. Aids 1998;12:2447-57.
56. Gordin F, Chaisson RE, Matts JP, Miller C, De Lourdes García M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000;283: 1445-50.
57. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351(9105): 786-92.
58. American Thoracic Society y Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
59. Centers for Disease Control and Prevention. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wldy Rep 2003;52:735-9.
60. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wldy Rep 2001;50:733-5.
61. Moreno S, Podzamczer D, Blázquez R, Iribarren JA, Ferrer E, Reparaz J, et al. Treatment of tuberculosis in HIV-infected patients: Safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. Aids 2001;15:1185-7.
62. Oliva J, Moreno S, Sanz J, Ribera E, Molina JA, Rubio R, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. Aids 2003;17:637-8.
63. th Conference on Retrovirus and Opportunistic Infections; 2003; Boston; 2003.
64. Veldkamp Al, Hoetelmans RM, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999;29:1586.
65. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000;49:185-9.
66. Weltman AC, Rose DN. The safety of Bacille Calmette-Guerin vaccination in HIV infection and AIDS. Aids 1993;7:149-57.
67. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
68. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
69. El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000;342:1085-92.
70. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998;178:1446-9.
71. Martínez E, Miró JM, González J, Mallolas J, Gatell JM. Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy. Aids 1999;13:147-8.
72. th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago, IL; 2001.
73. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137:239-50.
74. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial. Lancet 2000;355(9221):2106-11.
75. Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol 2001;22:255-61.
76. Arribas JR, Hernández-Albujar S, González-García JJ, Pena JM, González A, Canedo T, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. Aids 2000;14:979-85.
77. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, Van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995;332:700-5.
78. Havlir DV, Dube MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS [see comments]. Clin Infect Dis 1998;27:1369-75.
79. th Conference on Retrovirus and Opportunistic Infections; 2000; San Francisco; 2000.
80. Martínez E, García-Viejo MA, Marcos MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. Aids 2000;14:2615-7.
81. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793-8.
82. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-6.
83. Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-31.
84. Massini C, Pezzotti P, Miró JM, Martinez E, López Bernaldo de Quirós JC, Cinque P, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in AIDS patients after HAART: An international, observational study. Clinical Infectious Diseases. En prensa.
85. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:1049-56.
86. Wheat J, Hafner R, Wulfsohn M, Spencer P, Squires K, Powderly W, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. The National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators. Ann Intern Med 1993;118:610-6.
87. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002;34:277-84.
88. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998;339:1739-43.
89. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, et al. Comparison of oral fluconazole and itraconazole for progressive, non-meningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000;133:676-86.
90. Miró JM, Buira E, Mallolas J, Gallart T, Moreno A, Zamora L, et al. Linfocitos CD4+ e infecciones oportunistas y neoplasias en pacientes con infección por el virus de la inmunodeficiencia humans. Med Clin (Barc) 1994;102:566-70.
91. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891-6.
92. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990;322:161-5.
93. 3. Multicenter AIDS Cohort Study. J Infect Dis 1994;170:1284-7.
94. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000;342:1416-29.
95. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003;36:70-8.
96. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: Evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978;61:35-41.
97. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: Implications for transmission [In Process Citation]. Emerg Infect Dis 2000;6:265-72.
98. Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: A molecular epidemiology study. Emerg Infect Dis 2003;9:132-4.
99. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis. J Infect Dis 1998;178:1126-32.
100. Podzamczer D, Santín M, Jiménez J, Casanova A, Bolao F, Gudiol GR. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. Aids 1993;7:501-6.
101. El-Sadr WM, Luskin-Hawk R, Yurik TM, Walker J, Abrams D, John SL, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999;29:775-83.
102. Hirschel B, Lazzarin A, Chopard P, Opravil M, Furrer HJ, Ruttimann S, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
103. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, Nielsen TL, Van der Graaf Y, Frissen JP, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992;327:1836-41.
104. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1992;5:341-7.
105. Mallolas J, Zamora L, Gatell JM, Miró JM, Vernet E, Valls ME, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: A randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. Aids 1993;7:59-64.
106. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327:1842-8.
107. López Bernaldo de Quirós JC, Miró JM, Peña JM, Podzamczer D, Alberdi JC, Martinez E, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-67.
108. Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, et al. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/1. Aids 2001;15:1509-15.
109. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999;340:1301-6.
110. García Vázquez E, De Gorgolas Hernández M, García Delgado R, Fernández Guerrero ML. Suspensión de profilaxis frente a neumonía por Pneumocystis carinii en pacientes con tratamiento antirretroviral combinado eficaz. Estudio de 85 casos. Med Clin (Barc) 1999;113:89-90.
111. Soriano V, Dona C, Rodríguez-Rosado R, Barreiro P, González-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. Aids 2000;14:383-6.
112. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001;344:168-74.
113. Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte A, Govoni A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group. Clin Infect Dis 2003;36:645-51.
114. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-22.
115. Montoya JG, Remington JS. Toxoplasma gondii. En: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases (5th edition). Philadelphia: Churchill Livingstone, 2000; p. 2858-88.
116. Leport C, Chene G, Morlat P, Luft BJ, Rousseau F, Pueyo S, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: A double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 1996;173:91-7.
117. Ribera E, Fernández-Sola A, Juste C, Rovira A, Romero FJ, Armadans-Gil L, et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999;29:1461-6.
118. Derouin F, Leport C, Pueyo S, Morlat P, Letrillart B, Chene G, et al. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Aids 1996;10:1521-7.
119. th ECCATHI, 1997; 1997.
120. Torres RA, Barr M, Thorn M, Gregory G, Kiely S, Chanin E, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993;95:573-83.
121. Clotet B, Romeu J, Sirera G. Cerebral toxoplasmosis and prophylaxis for Pneumocystis carinii pneumonia. Ann Intern Med 1992;117:169.
122. Pedrol E, González-Clemente JM, Gatell JM, Mallolas J, Miró JM, Graus F, et al. Central nervous system toxoplasmosis in AIDS patients: Efficacy of an intermittent maintenance therapy. Aids 1990;4:511-7.
123. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996;22:268-75.
124. Podzamczer D, Miró JM, Ferrer E, Gatell JM, Ramón JM, Ribera E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis 2000;19:89-95.
125. Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1992;11:125-30.
126. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002;34:1243-50.
127. Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992;340(8820):637-8.
128. Torres RA, Weinberg W, Stansell J, Leoung G, Kovacs J, Rogers M, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997;24:422-9.
129. Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Aids 1996;10:1107-12.
130. Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C, et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis 1993;12:853-6.
131. Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. Aids 2001;15:583-9.
132. Wiselka MJ, Read R, Finch RG. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. J Infect 1996;33:227-9.
133. Fernández-Martín J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vilde JL. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991;35:2049-52.
134. Dhiver C, Milandre C, Poizot-Martin I, Drogoul MP, Gastaut JL, Gastaut JA. 5-Fluoro-uracil-clindamycin for treatment of cerebral toxoplasmosis. Aids 1993;7:143-4.
135. Ward DJ. Dapsone/pyrimethamine for the treatment of toxoplasmic encephalitis (B133-PoB 3277). En: VIII International Conference on AIDS; 1992; Amsterdam; 1992.
136. Derouin F, Piketty C, Chastang C, Chau F, Rouveix B, Pocidalo JJ. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother 1991;35:252-5.
137. Lacassin F, Schaffo D, Perronne C, Longuet P, Leport C, Vilde JL. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1995;39:276-7.
138. Pope-Pegram L, Gathe J, Bohn B, Piot D, Stool E. Treatment of presumed central nervous system texoplasmosis with doxycycline. En: VII International Conference on AIDS; 1991; Florencia; 1991.
139. Bookman KW, Gathe J, Stool E, Frazier R, Najjar A, Piot D. Utility of tetracycline derivatives in treatment of CNS toxoplasmosis (abstract no. PO-B10-1427). En: International Conference on AIDS; 1993; Berlin; 1993.
140. Rouquet RM, Carre P, Massip P, Estival M, Leophonte P. Acute respiratory distress due to Toxoplasma gondii in one AIDS patient. Recovery with an association pyrimethamine-doxycyclin (abstract no. PuB 7486). En: VIII International Conference on AIDS; 1992; Amsterdam; 1992.
141. Hagberg L, Palmertz B, Lindberg J. Doxycycline and pyrimethamine for toxoplasmic encephalitis. Scand J Infect Dis 1993;25:157-60.
142. Morris JT, Kelly JW. Effective treatment of cerebral toxoplasmosis with doxycycline. Am J Med 1992;93:107-8.
143. Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 1999;29:125-33.
144. th Conference on Retrovirus and Opportunistic Infections; 2000; 2000.
145. Jubault V, Pacanowski J, Rabian C, Viard JP. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy. Ann Med Interne (Paris) 2000;151:163-8.
146. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000;355(9222):2217-8.
147. Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study. J Infect Dis 2000;181:1635-42.
148. Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000;30:602-3.
149. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? Aids 1999;13:1647-51.
150. Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002;34:662-7.
151. Miró JM, López JC, Podzamczer D, Peña JM, Alberdi JC, Claramonte X. Discontinuation of toxoplasmic encephalitis (TE) maintenance therapy (MT) is safe in HIV-1 infected patients after immunological reconstitution with HAART. Long term follow-up of patients included in the GESIDA 04/98-B study (Abstract MoOrB1007). En: XIV International AIDS Conference; 2002; Barcelona; 2002.
152. Tortajada C, Pérez-Cuevas B, Moreno A, Martínez E, Mallolas J, García F, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:364-6.
153. López-Velez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 2001;7:394-5.
154. Pintado V, López-Vélez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001;7:291-300.
155. Casado JL, López-Vélez R, Pintado V, Quereda C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001;20:202-5.
156. Alvar J, Canavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997;10:298-319.
157. Ribera E, Ocana I, De Otero J, Cortés E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996;100:496-501.
158. López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejias ME, Gérgolas M. Amphotericin B lipid complex versus no-treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob. Chemother 2003. En prensa.
159. Sundar S, Jha TK, Thakur CP, Engel J, Sindermarm H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
160. Berenguer J, Cosin J, Miralles P, López JC, Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. Aids 2000;14:2946-8.
161. Upton SJ, Current WL. The species of Cryptosporidium (Apicomplexa: Cryptosporidiidae) infecting mammals. J Parasitol 1985;71:625-9.
162. Petersen C. Cryptosporidiosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 1992;15:903-9.
163. Lopez-Velez R, Tarazona R, Garcia Camacho A, Gómez-Mampaso E, Guerrero A, Moreira V, et al. Intestinal and extraintestinal cryptosporidiosis in AIDS patients. Eur J Clin Microbiol Infect Dis 1995;14:677-81.
164. Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998;279:384-6.
165. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK. Rifabutin but not darithromycin prevents cryptosporidiosis in persons with advanced HIV infection. Aids 2000;14:2889-93.
166. Canning EU, Hollister WS. Enterocytozoon bieneusi (Microspora): Prevalence and pathogenicity in AIDS patients. Trans R Soc Trop Med Hyg 1990;84:181-6.
167. Moreno Camacho A, Moreno Martínez A, Valls ME, Bordas JM, Piqué JM, Bombi JA, et al. Enteropatía crónica de etiología desconocida en pacientes con sida. Análisis de 40 casos. Med Clin (Barc) 1997;109: 452-6.
168. Felez MA, Miró JM, Mallolas J, Valls ME, Moreno A, Gatell JM, et al. Enteritis por Isospora belli en pacientes con SIDA. Descripción de nueve casos. Med Clin (Barc) 1990;95:84-8.
169. Moreno A, Gatell JM, Mensa J, Valls ME, Vila J, Claramonte X, et al. Incidencia de enteropatógenos en pacientes con infección por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1994;102:205-8.